Results 81 to 90 of about 53,238 (282)

From molecular promise to preclinical results: HDAC inhibitors in the race for healthy aging drugs

EMBO Molecular Medicine, 2019
Reversing or slowing the aging process brings great promise to treat or prevent age‐related disease, and targeting the hallmarks of aging is a strategy to achieve this.
Rebecca L McIntyre, Eileen G Daniels, Marte Molenaars, Riekelt H Houtkooper, Georges E Janssens   +4 more
doaj   +1 more source

Histone Deacetylases and their Inhibitors in Cancer Epigenetics

Diseases, 2019
Histone deacetylases (HDAC) and histone deacetylase inhibitors (HDACi) have greatly impacted the war on cancer. Their role in epigenetics has significantly altered the development of anticancer drugs used to treat the most rare, persistent forms of ...
Kelly N. Hassell
doaj   +1 more source

Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors [PDF]

, 2010
Histone deacetylase inhibitors (HDI) dampen cellular innate immune response by decreasing interferon production and have been shown to increase the growth of vesicular stomatitis virus and HSV.
Atkins, H, Bell, JC, Breitbach, C, Cox, J, De Silva, N, Diallo, JS, Falls, T, Guimond, T, Huang, B, Kirn, D, Le Boeuf, F, MacTavish, H, McCart, AJ, Simmons, JG, Stanford, M, Thorne, S   +15 more
core   +1 more source

Histone Deacetylase Inhibitors for Cancer Therapy [PDF]

Epigenetics, 2006
The epigenome of cancer cells is determined by DNA methylation and an array of post-translational modifications of the core histones. Epigenetic abnormalities are commonly found in human tumors and importantly, they can be reversed by pharmacologic inhibitors.
Tae-You, Kim, Yung-Jue, Bang, Keith D, Robertson   +2 more
openaire   +2 more sources

Natural Products as Geroprotective Modulators in Diabetic Nephropathy: A Mechanistic Framework Integrating Aging Hallmarks and the AMPK–SIRT1–Nrf2 Axis

Aging and Cancer, EarlyView.
Natural products target the aging kidney in diabetic nephropathy by restoring the AMPK–SIRT1–Nrf2 axis, reducing oxidative stress, inflammation, fibrosis, and cellular senescence while enhancing mitochondrial biogenesis and antioxidant defenses.
Sherif Hamidu, Latif Adams, Eunice Ampem‐Danso, Justice Kumi, Abigail Aning, Fatima Hamidu, Mustapha Abdul Mumin Mohammed, Ayuba Nii Darku Ankrah, Seth Kwabena Amponsah   +8 more
wiley   +1 more source

Human neuronal cells: epigenetic aspects

Biomolecular Concepts, 2013
Histone acetyltransferases (HATs) and histone deacetylases (HDACs) promote histone posttranslational modifications, which lead to an epigenetic alteration in gene expression. Aberrant regulation of HATs and HDACs in neuronal cells results in pathological
Kukucka Jessica, Wyllie Tessa, Read Justin, Mahoney Lauren, Suphioglu Cenk   +4 more
doaj   +1 more source

HDAC inhibition is associated to valproic acid induction of early megakaryocytic markers [PDF]

, 2006
Valproic acid (VPA), a histone deacetylase inhibitor, causes differentiation in different cell lines and in a cell-specific manner; yet, its effect on megakaryocytic (MK) differentiation has not been studied.
Ciccarelli, Carmela, Giampaolo, Adele, Giampiero, Macioce, Hassan, Hamisa J, Marampon, Francesco, Mattia, Gianfranco, Milazzo, Luisa, Pascuccio, Massimiliano, Vulcano, Francesca, Zani, Bianca M   +9 more
core  

Disengaging the Engine: Histone Deacetylases 1 and 2‐Mediated Acetylation of Hexokinase‐2 Regulates Energy Metabolism in Microglia Following Intracerebral Hemorrhage

Advanced Science, EarlyView.
This study demonstrates that HDAC1/2 knockout in microglia alleviates neurological deficits, preserves white matter, and accelerates hematoma clearance after ICH. HDAC1/2 inhibition reduces HK2 acetylation, shifts metabolism from glycolysis to fatty acid oxidation, reduces inflammation, and enhances phagocytosis.
Zhiwen Jiang, Heng Yang, Xinjie Gao, Zengyu Zhang, Ruiyuan Weng, Yuchao Fei, Jiabin Su, Hanqiang Jiang, Wei Ni, Yuxiang Gu   +9 more
wiley   +1 more source

The promising combination therapy strategy for overcoming resistance to histone deacetylase inhibitors in diffuse large B‐cell lymphoma

Clinical and Translational Discovery, 2022
Single histone deacetylases inhibitors (HDACis) or current combination therapies show limited clinical efficiency in facing the striking heterogeneity of diffuse large B‐cell lymphoma (DLBCL). This commentary reviews the research conducted by Wang et al.
Haixiang Pei, Yihua Chen
doaj   +1 more source

NNMT Orchestrates Metabolic‐Epigenetic Reprogramming to Drive Macrophage‐Myofibroblast Transition in Hypertrophic Scarring

Advanced Science, EarlyView.
In macrophage‐myofibroblast transition, upregulated NNMT depletes S‐Adenosylmethionine‌ (SAM) and nicotinamide adenine dinucleotide(NAD+), thereby triggering epigenetic reprogramming via Histone H3 Lysine 27 acetylation (H3K27ac) accumulation at the promoter region of master transcription factor Prrx1.
Xiwen Dong, Weinan Guo, Yuxuan Qian, Wenyan Jin, Xiaozhen Li, Jingyuan Yang, Qingrong Ni, Shuang Wu, Fanni Li, Hua Wang, Chunying Li, Hong Cai   +11 more
wiley   +1 more source